{
  "docId": "019de076-8fd6-709e-8689-4f849e880c13",
  "docSlug": "045f5237a1062f1479093c113a295dbd",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 29 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 29,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8fd6-709e-8689-4f849e880c13/20",
  "deckHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13",
  "deckJsonHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13.json",
  "deckAnchorHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.07,
        "y": 0.3
      },
      "kind": "list",
      "text": "≥10 fold more potent than orexin A; >5,000-fold selectivity relative to OX1R",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f2fbe22-8e1b-40d6-a6f8-8e206a70738c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.07,
        "y": 0.55
      },
      "kind": "list",
      "text": "Orally bioavailable; PK profile supportive of once-daily dosing; Mimics natural sleep/wake cycle; Half life of 8-10 hours",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f664e09d-850e-40d3-be11-07255ae0de29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "ALKS 2680 initial phase 1 data demonstrated desired pharmaceutical properties:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29b02d83-ab63-468a-b981-dd1c1e55db3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "ALKS 2680 is a highly potent, selective OX2R agonist",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0b50a71-1a3c-4281-b2ea-4bee3f44f6ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "aData from preclinical studies using CHO (Chinese hamster ovary) cells. OX1R: orexin 1 receptor; OX2R: orexin 2 receptor; PK: pharmacokinetic; NT1: narcolepsy type 1; NT2: narcolepsy type 2; IH: idiopathic hypersomnia",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da90a0ac-640e-4718-8bd9-e33bcce5c040",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "table",
      "text": "Program Status: Phase 1b proof-of-concept study underway; Recently completed phase 1b NT1 cohort; Phase 2 NT1 doses selected; Phase 1b NT2 and IH proof-of-concept data expected H1 2024; Phase 2 NT2 dose selection; Phase 2 NT1 study initiation expected H1 2024",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "554a4bc1-ef6d-4d3f-b0bc-2625fe44981d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALKS 2680: Investigational Oral Orexin 2 Receptor Agonist for the Treatment of Narcolepsy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e21c7ae-8ddd-4ce4-8d02-e6d813718690",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "20221315-1e65-40ea-8c31-6b3444e8a6b9",
      "evidence": "The slide presents data in a table format, which is a clear instantiation of table data.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 20,
      "beatId": "684f34f1-a86c-4f27-a384-190507ef00a2",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Solution",
      "beatSlug": null,
      "evidence": "The deck presents Alkermes' solution with ALKS 2680 and its development pipeline.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 16,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "58d89332-74ab-4a79-b132-80fa9e87fcdc",
      "evidence": "The deck presents a problem statement on orexin dysfunction and Alkermes' solution.",
      "position": 0,
      "objective": "What if Alkermes doesn't address orexin dysfunction?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 23,
      "from": 20,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "6855712d-cfcc-4ba8-90cd-9f606eb2639a",
      "evidence": "The deck presents results from ALKS 2680 clinical trials.",
      "position": 1,
      "objective": "What are the results of ALKS 2680?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}